RT Journal Article
SR Electronic
T1 P149 Clinical worsening in non-adherent belimumab treatment in SLE
JF Lupus Science & Medicine
JO Lupus Sci Med
FD Lupus Foundation of America
SP A155
OP A156
DO 10.1136/lupus-2024-el.203
VO 11
IS Suppl 1
A1 Navarro, Marta de la Rubia
A1 García, Elena Grau
A1 Monreal, Ma Jesús Cuellar
A1 Álvarez, Iago Alcántara
A1 Verdejo, Inmaculada Chalmeta
A1 Charia, Hikmat
A1 Puig, Luis González
A1 Huaylla Quispe, Anderson Víctor
A1 Cortés, José Ivorra
A1 Leal, Samuel
A1 Cordellat, Isabel Martínez
A1 Sánchez, Laura Mas
A1 Muñoz Martínez, Pablo Francisco
A1 Albuixech, Rosa Negueroles
A1 Oller Rodríguez, José Eloy
A1 Castro, Daniel Ramos
A1 Bárcena, Carmen Riesco
A1 Novés, Alba Torrat
A1 Sugrañes, Ernesto Tovar
A1 Bernabeu, Elvira Vicens
A1 Mañes, Belén Villanueva
A1 Olmos, Inés Cánovas
A1 Herranz, Carmen Nájera
A1 Román Ivorra, José Andrés
YR 2024
UL http://lupus.bmj.com/content/11/Suppl_1/A155.2.abstract
AB Objective The objective is to analyze the association between therapeutic adherence and disease activity in SLE patients.Methods An observational, prospective study in SLE patients (SLICC/ACR criteria), treated whit subcutaneous Belimumab (200 mg/week) was made. Disease activity was measured by SLEDAI in three consecutive visits, and it was considered clinical worsening an increase of SLEDAI-score of ≥4 point. Persistence and adherence of Belimumab data during the follow-up were collected and were calculated based on the number of drug dispensing. Poor therapeutic adherence was established under the 95%.Results Thirty-one prescriptions of Belimumab were registered (83.9% women) with a mean age of 48.1 (14.9) years. Time since the diagnosis was 12.5 (6.29) years and treatment period were 2.2 (1.4) years. Fifteen patients were considered as non-adherent (48.4%).Persistence and disease activity data in each group were showed in the table 1.View this table:Abstract P149 Table 1 Poor adherence was secondary to clinical improvement (66.67%), recurrent infections (13.33%), surgery (6.67%), pregnancy (6.67%) and inability to drug collect due to COVID-19 pandemic (6.67%). Non-adherent group showed worse SLEDAI-score than adherent group in V0, despite of a similar SLEDAI-score at V2 in both groups was observed. There was an association between poor therapeutic adherence and high delta_SLEDAI (p=0.046).Conclusions We observed an association between poor therapeutic adherence and delta_SLEDAI. The high SLEDAI-score at the beginning of the study in non-adherent group would be due to clinical manifestations, despite of the similar serological activity in both groups.